PERCEPTIVE ADVISORS LLC
Q3 2023 13F-HR Holdings
Net value change ($000)
-456,922
(-13.2%)
New positions
9
Sold out positions
10
Turnover %
15.1%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IMVT | 98,570 | 205.9% |
| SLNO | 81,259 | 858.0% |
| ARGX | 47,148 | 175.3% |
| APGE | 38,934 | NEW |
| RVMD | 36,587 | NEW |
| TNGX | 27,238 | NEW |
| NUVL | 20,689 | 22.4% |
| CymaBay Therapeutics, Inc. | 19,405 | 47.5% |
| RayzeBio, Inc. | 17,245 | NEW |
| BBIO | 16,037 | 53.3% |
Top Reduces (Value $000, Stocks/ETFs)
| Cerevel Therapeutics Holdings, Inc. | -100,481 | -31.3% |
| APLS | -73,977 | -100.0% |
| REATA PHARMACEUTICALS INC | -68,334 | -100.0% |
| AMLX | -55,897 | -53.2% |
| MDGL | -51,788 | -74.0% |
| VIR | -48,036 | -100.0% |
| LIANY | -45,471 | -34.6% |
| IOVA | -44,385 | -44.9% |
| TMCI | -32,672 | -57.6% |
| VRNA | -27,638 | -29.7% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
23,512
(0.8% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|